AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 209 filers reported holding AMICUS THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $336,745,870 | -3.1% | 27,692,917 | +0.1% | 11.23% | +11.7% |
Q2 2023 | $347,446,237 | +13.3% | 27,662,917 | 0.0% | 10.06% | +11.0% |
Q1 2023 | $306,781,750 | -9.1% | 27,662,917 | +0.1% | 9.06% | -4.4% |
Q4 2022 | $337,520,017 | +18.1% | 27,642,917 | +1.0% | 9.48% | +14.3% |
Q3 2022 | $285,773,000 | -1.1% | 27,372,917 | +1.8% | 8.29% | -8.3% |
Q2 2022 | $288,858,000 | +10.7% | 26,895,532 | -2.4% | 9.05% | +73.1% |
Q1 2022 | $260,954,000 | -57.5% | 27,555,845 | -48.1% | 5.23% | +10.5% |
Q4 2021 | $613,524,000 | +141.9% | 53,118,886 | +100.0% | 4.73% | +28.4% |
Q3 2021 | $253,643,000 | -43.1% | 26,559,443 | -42.6% | 3.68% | +27.3% |
Q2 2021 | $445,780,000 | +97.4% | 46,242,658 | +102.3% | 2.90% | +1.4% |
Q1 2021 | $225,870,000 | -61.0% | 22,861,329 | -9.0% | 2.86% | -54.1% |
Q4 2020 | $579,837,000 | +63.5% | 25,112,048 | -0.0% | 6.22% | +20.2% |
Q3 2020 | $354,723,000 | -6.6% | 25,122,048 | -0.2% | 5.18% | -15.8% |
Q2 2020 | $379,750,000 | +63.2% | 25,182,364 | 0.0% | 6.15% | +1.6% |
Q1 2020 | $232,685,000 | -4.9% | 25,182,364 | +0.2% | 6.06% | +24.6% |
Q4 2019 | $244,789,000 | +24.0% | 25,132,364 | +2.1% | 4.86% | -8.5% |
Q3 2019 | $197,369,000 | -26.5% | 24,609,700 | +14.4% | 5.32% | -13.7% |
Q2 2019 | $268,438,000 | -8.8% | 21,509,486 | -0.6% | 6.16% | -25.8% |
Q1 2019 | $294,297,000 | +53.5% | 21,639,486 | +4.4% | 8.30% | +13.8% |
Q4 2018 | $191,701,000 | -23.4% | 20,724,424 | +0.1% | 7.30% | +9.1% |
Q3 2018 | $250,196,000 | -20.0% | 20,694,424 | +3.3% | 6.69% | -18.4% |
Q2 2018 | $312,782,000 | +3.9% | 20,024,424 | 0.0% | 8.20% | -2.8% |
Q1 2018 | $301,167,000 | +17.0% | 20,024,424 | +11.9% | 8.44% | -1.1% |
Q4 2017 | $257,417,000 | -52.3% | 17,888,597 | -50.0% | 8.53% | -17.2% |
Q3 2017 | $539,520,000 | +209.8% | 35,777,194 | +106.8% | 10.30% | +17.5% |
Q2 2017 | $174,178,000 | +41.2% | 17,296,672 | 0.0% | 8.76% | +24.8% |
Q1 2017 | $123,325,000 | +43.5% | 17,296,672 | 0.0% | 7.02% | +14.9% |
Q4 2016 | $85,964,000 | -17.7% | 17,296,672 | +22.5% | 6.11% | -9.3% |
Q3 2016 | $104,463,000 | +25.5% | 14,116,644 | -7.4% | 6.74% | +16.9% |
Q2 2016 | $83,207,000 | -35.4% | 15,239,444 | 0.0% | 5.77% | -48.9% |
Q1 2016 | $128,773,000 | -12.9% | 15,239,444 | 0.0% | 11.30% | +3.3% |
Q4 2015 | $147,823,000 | -57.9% | 15,239,444 | -47.2% | 10.94% | -22.1% |
Q3 2015 | $351,266,000 | +71.9% | 28,878,888 | +100.0% | 14.03% | +14.1% |
Q2 2015 | $204,318,000 | +30.1% | 14,439,444 | 0.0% | 12.30% | +0.8% |
Q1 2015 | $157,101,000 | +30.8% | 14,439,444 | 0.0% | 12.21% | +21.2% |
Q4 2014 | $120,136,000 | +63.6% | 14,439,444 | +17.0% | 10.08% | +27.8% |
Q3 2014 | $73,420,000 | +78.1% | 12,339,444 | 0.0% | 7.88% | +95.0% |
Q2 2014 | $41,214,000 | +1960.7% | 12,339,444 | +1177.0% | 4.04% | +1825.2% |
Q1 2014 | $2,000,000 | – | 966,300 | – | 0.21% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |